A randomized prospective analysis of alteration of hemostatic function in patients receiving tranexamic acid and hydroxyethyl starch (130/0.4) undergoing off pump coronary artery bypass surgery Full Text
Annals of Cardiac Anaesthesia, 04/18/2012
Chakravarthy M et al. – Concomitant use of tranexamic acid (TA) with hydroxyl ethyl starch (HES) appears to reverse these changes without causing any adverse effects in patients undergoing OPCAB surgery.Methods
- Thromboelastogram (TEG) was used to assess the effect of the combination of HES and TA.
- With ethical committee approval and patient's consent, 100 consecutive patients were recruited for the study.
- Surgical and anesthetic techniques were standardized
- Patients fulfilling the inclusion criteria were randomly allocated into 4 groups of 25 each.
- The patients in group A received 20ml/kg of HES (130/0.4), 10mg/kg of T.A over 30minutes followed by infusion of 1mg/kg/hr over the next 12hrs.
- The patients in group B received Ringer's lactate+TA at same dose.
- The patients in the Group C received 20ml/kg of HES.
- Group D patients received RL.
- Fluid therapy was goal directed.
- Total blood loss was assessed.
- Reaction time (r), α angle, maximum amplitude (MA) values of TEG were assessed at baseline, 12, 36hrs.
- The possible perioperative myocardial infraction (MI) was assessed by electrocardiogram (ECG) and troponin T values at the baseline, postoperative day 1.
- Duration on ventilator, length of stay (LOS) in the intensive care unit (ICU) were also assessed.
- The demographical profile was similar among the groups.
- Use of HES increased blood loss significantly (P<0.05).
- Concomitant use of TA reduced blood loss when used along with HES.
- r value was prolonged at 12hours in all the groups and α angle was reduced at 12hours in all the groups, where as MA value was reduced at 12th hour in the HES group compared to the baseline and increased in TA + HES group.
- These findings were statistically significant.
- No significant change in Troponin T values/ ECG, duration of ventilation and LOS ICU was observed.
- No adverse events was noticed in any of the four groups. HES (130/0.4) used at a dose of 20ml/kg seems to produce coagulopathy causing increased blood loss perioperatively.
- Hemodilution produced by fluid therapy seems to produce Coagulopathy as observed by TEG parameters.